Paul Feuerstadt, MD, FACG, AGAF
About
Biography
A native of Long Island, New York, Dr. Feuerstadt attended the University of Pennsylvania where he earned his Bachelor of Arts degree in Biology, with distinction in research and graduated Summa Cum Laude.
Following completion of his undergraduate training, Dr. Feuerstadt attended the Weill Medical College of Cornell University in Manhattan, New York where he earned his Medical Doctor degree and stayed at New York Presbyterian Hospital/Weill Cornell medical center for his internship and residency in Internal Medicine. Following completion of his residency Dr. Feuerstadt then moved on to the Montefiore Medical Center in the Bronx, New York for his clinical fellowship training.
Throughout Dr. Feuerstadt’s training and practice he has been actively involved in research and other academic pursuits. His areas of interest include chronic diarrheal syndromes with a specific focus on Clostridiodes difficile infection, irritable bowel syndrome (IBS) and ischemic diseases of the gut. He has presented his research extensively at national meetings and has authored and co-authored many manuscripts, textbook chapters and online modules. Another passion of Dr. Feuerstadt’s is teaching, frequently giving lectures locally, regionally and nationally. Dr. Feuerstadt founded a website entitled "Everythingcdifficile.com" as an educational resource for patients and providers about this infectious disease. Finally, he is passionate about mentoring the fellows in the Division of Digestive Disease at Yale-New Haven Hospital where he holds a clinical appointment as an Assistant Clinical Professor of Medicine.
His clinical practice is his ultimate passion filling the majority of his work time as he sees a broad spectrum of patients with gastrointestinal and hepatic disease. Dr. Feuerstadt is affiliated with the St. Raphael campus of Yale-New Haven Hospital, Yale-New Haven Hospital, and Milford Hospital.
Appointments
Digestive Diseases
Associate Clinical ProfessorPrimary
Other Departments & Organizations
Education & Training
- Fellow
- Montefiore Medical Center-Albert Einstein College of Medicine (2010)
- Categorical Resident
- New York Presbyterian Hospital-Weill Cornell Medical Center (2007)
- MD
- Weill Cornell Medical College (2004)
- BA
- University of Pennsylvania (2000)
Research
Overview
Medical Subject Headings (MeSH)
ORCID
0000-0002-7643-9576
Research at a Glance
Yale Co-Authors
Research Interests
Rabia Rizwan, MBBS
Abdelkader Chaar, MD, FACP
Kanika Sehgal, MBBS
Treatment Outcome
Publications
2024
Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI
Kraft C, Sims M, Silverman M, Louie T, Feuerstadt P, Huang E, Khanna S, Berenson C, Wang E, Cohen S, Korman L, Lee C, Kelly C, Odio A, Cook P, Lashner B, Ramesh M, Kumar P, De A, Memisoglu A, Lombardi D, Hasson B, McGovern B, von Moltke L, Pardi D. Integrated Safety and Efficacy Analyses of Phase 3 Trials of a Microbiome Therapeutic for Recurrent CDI. Infectious Diseases And Therapy 2024, 1-17. PMID: 38941068, DOI: 10.1007/s40121-024-01007-z.Peer-Reviewed Original ResearchConceptsTreatment-emergent adverse eventsPhase 3 trialRCDI rateAnalysis of treatment-emergent adverse eventsTreatment-related treatment-emergent adverse eventsStandard-of-care antibioticsHigh-risk patientsClostridioides difficile infectionPreventing rCDIRenal impairment/failureAbdominal painRecurrent CDIEfficacy analysisAdverse eventsTreatment-relatedPrevent recurrencePrevalent comorbiditiesRCDIWeeksAntibioticsPatientsComorbiditiesEfficacyPlaceboMicrobiomeLive biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection
Sehgal K, Feuerstadt P. Live biotherapeutic products: a capstone for prevention of recurrent Clostridiodes difficile infection. Frontiers In Microbiomes 2024, 3: 1399440. DOI: 10.3389/frmbi.2024.1399440.Peer-Reviewed Original ResearchAltmetricConceptsClostridiodes difficile infectionLive biotherapeutic productsFecal microbiota transplantationStandard of careDifficile infectionFDA approvalHealthcare-acquired diarrheaReduction of recurrenceReducing CDI recurrencePrevention of recurrenceGut microbiotaGastrointestinal microbiotaCDI recurrenceAntimicrobial therapyMicrobiotaInfection onsetMicrobiota transplantationRecurrenceClinical practiceInfectionBiotherapeutic productsTherapyFDADeficiencyPreventionThe Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond
Allegretti J, Khanna S, Mullish B, Feuerstadt P. The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond. Gastroenterology 2024 PMID: 38754739, DOI: 10.1053/j.gastro.2024.05.004.Peer-Reviewed Original ResearchAltmetricConceptsFecal microbiota transplantationMicrobiome therapeuticsNext generation sequencingIntestinal ecosystemHuman microbiotaMicrobiota restorationGeneration sequencingGastrointestinal microbiomeMicrobiota transplantationMicrobiotaExtraintestinal conditionsMitigate diseaseIncreased abilityEcosystemMicrobiomeTherapeuticsGastrointestinal diseasesSequenceMo1345 ACUTE VASCULAR INTESTINAL DISEASE IN PATIENTS WITH END-STAGE RENAL DISEASE: A NATIONAL ANALYSIS
Rizwan R, Chaar A, Sehgal K, Richter T, Nawaz A, Patel S, Feuerstadt P. Mo1345 ACUTE VASCULAR INTESTINAL DISEASE IN PATIENTS WITH END-STAGE RENAL DISEASE: A NATIONAL ANALYSIS. Gastroenterology 2024, 166: s-1033. DOI: 10.1016/s0016-5085(24)02849-x.Peer-Reviewed Original ResearchSa1898 RACIAL DISPARITIES IN PATIENTS HOSPITALIZED WITH CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDY
Chaar A, Rizwan R, Patel S, Sehgal K, Richter T, Nawaz A, Feuerstadt P. Sa1898 RACIAL DISPARITIES IN PATIENTS HOSPITALIZED WITH CLOSTRIDIOIDES DIFFICILE INFECTION: A POPULATION-BASED STUDY. Gastroenterology 2024, 166: s-569-s-570. DOI: 10.1016/s0016-5085(24)01783-9.Peer-Reviewed Original ResearchSu1009 RACIAL DISPARITIES IN ACUTE VASCULAR INTESTINAL DISEASES: A NATIONAL ANALYSIS
Sehgal K, Chaar A, Rizwan R, Richter T, Feuerstadt P. Su1009 RACIAL DISPARITIES IN ACUTE VASCULAR INTESTINAL DISEASES: A NATIONAL ANALYSIS. Gastroenterology 2024, 166: s-634-s-635. DOI: 10.1016/s0016-5085(24)01916-4.Peer-Reviewed Original ResearchClinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States
Lembo A, Cash B, Lu M, Terasawa E, Terreri B, Du S, Ayyagari R, Feuerstadt P, Moshiree B, Westermeyer B, Pi S, Boules M. Clinical Outcomes Before and After Prucalopride Treatment: An Observational Study in Patients With Chronic Idiopathic Constipation in the United States. Clinical And Translational Gastroenterology 2024, 15: e00687. PMID: 38357940, PMCID: PMC11124638, DOI: 10.14309/ctg.0000000000000687.Peer-Reviewed Original ResearchAltmetricConceptsConstipation-related symptomsChronic idiopathic constipationProportion of patientsComplications 6 monthsIdiopathic constipationRetrospective cohort analysisDecreased 6 monthsMedicare Supplemental databaseICD-10 procedurePatient ageTreatment initiationClinical outcomesPrucalopride treatmentCohort analysisComplicationsPrucaloprideObservational studyPatientsSupplemental databaseICD-10 Procedure Coding SystemCommercial ClaimsDiagnosis codesICD-10-CMSymptomsClinical ModificationEfficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection
Feuerstadt P, Allegretti J, Dubberke E, Guo A, Harvey A, Yang M, Garcia-Horton V, Fillbrunn M, Tillotson G, Bancke L, LaPlante K, Garey K, Khanna S. Efficacy and Health-Related Quality of Life Impact of Fecal Microbiota, Live-jslm: A Post Hoc Analysis of PUNCH CD3 Patients at First Recurrence of Clostridioides difficile Infection. Infectious Diseases And Therapy 2024, 13: 221-236. PMID: 38236515, PMCID: PMC10828144, DOI: 10.1007/s40121-023-00907-w.Peer-Reviewed Original ResearchCitationsAltmetricConceptsRecurrence of CDIHealth-related quality of lifeTreatment successPost hoc analysisAntibiotic treatmentDouble-blind placebo-controlled clinical trialPlacebo-controlled clinical trialBlinded phaseHealth-related qualityProbability of treatment successBaseline to weekOdds of recurrenceBaseline patient characteristicsHealth-related quality of life impactCD3- patientsFecal microbiotaAnalyzed efficacyDifficile infectionEligible patientsPatient characteristicsClinical trialsPlaceboRecurrenceEffective treatmentPatientsErratum: Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection.
Feuerstadt P, LaPlante K. Erratum: Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection. The American Journal Of Gastroenterology 2024 PMID: 38180907, DOI: 10.14309/ajg.0000000000002649.Peer-Reviewed Original ResearchAltmetricEfficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection
Feuerstadt P, LaPlante K. Efficacy and Practical Implementation of Fecal Microbiota Spores, Live-BRPK: A Novel Approach for Preventing Recurrent Clostridioides difficile Infection. The American Journal Of Gastroenterology 2024, 119: s22-s26. PMID: 38153222, DOI: 10.14309/ajg.0000000000002582.Peer-Reviewed Original ResearchCitationsAltmetricMeSH Keywords and Concepts
Links & Media
Get In Touch
Events
Yale Only Paul Feuerstadt, MD, FACG, AGAF